Targeted treatments for fragile X syndrome
Open accessThe DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Abstract
Fragile X syndrome (FXS) is the most common identifiable genetic cause of intellectual disability and autistic spectrum disorders (ASD), with up to 50% of males and some females with FXS meeting criteria for ASD. Autistic features are present in a very high percent of individuals with FXS, even those who do not meet full criteria for ASD. Recent major advances have been made in the understanding of the neurobiology and functions of FMRP, the FMR1(fragile X mental retardation 1) gene product, which is absent or reduced in FXS, largely based on work in the fmr1 knockout mouse model. FXS has emerged as a disorder of synaptic plasticity associated with abnormalities of long-term depression and long-term potentiation and immature dendritic spine architecture, related to the dysregulation of dendritic translation typically activated by group I mGluR and other receptors. This work has led to efforts to develop treatments for FXS with neuroactive molecules targeted to the dysregulated translational pathway. These agents have been shown to rescue molecular, spine, and behavioral phenotypes in the FXS mouse model at multiple stages of development. Clinical trials are underway to translate findings in animal models of FXS to humans, raising complex issues about trial design and outcome measures to assess cognitive change that might be associated with treatment. Genes known to be causes of ASD interact with the translational pathway defective in FXS, and it has been hypothesized that there will be substantial overlap in molecular pathways and mechanisms of synaptic dysfunction between FXS and ASD. Therefore, targeted treatments developed for FXS may also target subgroups of ASD, and clinical trials in FXS may serve as a model for the development of clinical trial strategies for ASD and other cognitive disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inositol trisphosphate and calcium signalling
Berridge, M. J. (1993) · Nature · doi:10.1038/361315a0 · Cited by 6,545 · cited 2×
“Of the group 1 mGluRs, mGluR1 receptors are present mainly in the cerebellum and hippocampus, while mGluR5 receptors are present throughout the brain except in the cerebellum (Bear et al. 2004; Bear 2005).”
BackgroundVerkerk, A. J. M. H., Pieretti, M., Sutcliffe, J. S., Fu, Y.-H., Kuhl, D. P. A., Pizzuti, A., Reiner, O., Richards, S., Victoria, M. F., Zhang, F., et al. (1991) · Cell · doi:10.1016/0092-8674(91)90397-h · Cited by 3,481 · cited 2×
“…a trinucleotide repeat (CGG) expansion mutation of >200 repeats (full mutation) in the promoter of the FMR1 (fragile X mental retardation 1) gene (Verkerk et al. 1991), which leads to methylation and transcriptional silencing of the FMR1 promoter with consequent loss or significant reduction of…”
BackgroundFunctional impact of global rare copy number variation in autism spectrum disorders
Pinto, D., Pagnamenta, A. T., Klei, L., Anney, R., Merico, D., Regan, R., Conroy, J., Magalhaes, T. R., Correia, C., Abrahams, B. S., et al. (2010) · Nature · doi:10.1038/nature09146 · Cited by 2,013 · cited 1×
“Array studies in cohorts of patients with ASDs and mapping/mutation analyses in families segregating ASDs are generating a large list of genes implicated in autism which can be mapped onto specific brain pathways (Wang et al. 2010a; Marshall et al. 2008; Awadalla et al. 2010; Pinto et al. 2010).”
BackgroundStructural Variation of Chromosomes in Autism Spectrum Disorder
Marshall, C. R., Noor, A., Vincent, J. B., Lionel, A. C., Feuk, L., Skaug, J., Shago, M., Moessner, R., Pinto, D., Ren, Y., et al. (2008) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2007.12.009 · Cited by 1,815 · cited 1×
“Array studies in cohorts of patients with ASDs and mapping/mutation analyses in families segregating ASDs are generating a large list of genes implicated in autism which can be mapped onto specific brain pathways (Wang et al. 2010a; Marshall et al. 2008; Awadalla et al. 2010; Pinto et al. 2010).”
BackgroundThe mGluR theory of fragile X mental retardation
Bear, M. F., Huber, K. M., & Warren, S. T. (2004) · Trends in Neurosciences · doi:10.1016/j.tins.2004.04.009 · Cited by 1,580 · cited 6×
“…cognitive difficulty, strabismus, enhanced anxiety, coordination problems and loose stools, and are effects that have been proposed to occur in a setting of exaggeration of mGluR-mediated protein synthesisdependent processes that would normally be inhibited by FMRP (Bear et al. 2004; Bear 2005).”
BackgroundInfluentialAltered synaptic plasticity in a mouse model of fragile X mental retardation
Huber, K. M., Gallagher, S. M., Warren, S. T., & Bear, M. F. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.122205699 · Cited by 1,349 · cited 4×
“This dysregulated dendritic expression (either temporally, spatially, or quantitatively) of multiple FMRP mRNA ligands results in abnormal synaptic plasticity, including enhanced mGluR-activated hippocampal (Huber et al. 2002) and cerebellar (Koekkoek et al.”
BackgroundInfluentialBrown, V., Jin, P., Ceman, S., Darnell, J. C., O'Donnell, W. T., Tenenbaum, S. A., Jin, X., Feng, Y., Wilkinson, K. D., Keene, J. D., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00568-2 · Cited by 1,109 · cited 4×
“1b, and others (Darnell et al. 2001; Brown et al. 2001; Chen et al. 2003; Miyashiro et al. 2003; Park et al. 2008; Zhang et al. 2001; Muddashetty et al. 2007; Goebel-Goody et al. 2010; Westmark and Malter 2007; Shumbos et al. 2010).”
BackgroundInfluentialGABAergic Interneurons Implications for Understanding Schizophrenia and Bipolar Disorder
Benes, F. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00225-1 · Cited by 1,082
Fragile X Syndrome: Loss of Local mRNA Regulation Alters Synaptic Development and Function
Bassell, G. J., & Warren, S. T. (2008) · Neuron · doi:10.1016/j.neuron.2008.10.004 · Cited by 1,051 · cited 1×
“Therefore, FMRP is thought to regulate translation at the dendrite in response to neural activation, thereby modulating synaptic plasticity and dendritic morphology (for reviews, see Bagni and Greenough 2005; Grossman et al. 2006; Bassell and Warren 2008).”
BackgroundAbnormal dendritic spines in fragile X knockout mice: Maturation and pruning deficits
Comery, T. A., Harris, J. B., Willems, P. J., Oostra, B. A., Irwin, S. A., Weiler, I. J., & Greenough, W. T. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.10.5401 · Cited by 1,046 · cited 4×
“2005), and abnormal dendritic spine morphology (Grossman et al. 2006; Comery et al. 1997; Irwin et al. 2002; Nimchinsky et al. 2001).”
BackgroundInfluential
Cited by
Hagerman, R. J., Berry-Kravis, E., Hazlett, H. C., Bailey, D. B., Moine, H., Kooy, R. F., Tassone, F., Gantois, I., Sonenberg, N., Mandel, J. L., et al. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.65 · Cited by 838
Self-citationEpidemiology of fragile X syndrome: A systematic review and meta‐analysis
Hunter, J., Rivero‐Arias, O., Angelov, A., Kim, E., Fotheringham, I., & Leal, J. (2014) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.36511 · Cited by 442
Fragile X syndrome: a review of associated medical problems
Kidd, S. A., Lachiewicz, A., Barbouth, D., Blitz, R. K., Delahunty, C., McBrien, D., Visootsak, J., & Berry-Kravis, E. (2014) · Pediatrics · doi:10.1542/peds.2013-4301 · Cited by 255
Self-citationAnagnostou, E., Jones, N., Huerta, M., Halladay, A. K., Wang, P., Scahill, L., Horrigan, J. P., Kasari, C., Lord, C., Choi, D., et al. (2015) · Autism · doi:10.1177/1362361314542955 · Cited by 210
High MMP-9 activity levels in fragile X syndrome are lowered by minocycline
Dziembowska, M., Pretto, D. I., Janusz, A., Kaczmarek, L., Leigh, M. J., Gabriel, N., Durbin‐Johnson, B., Hagerman, R. J., & Tassone, F. (2013) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.36023 · Cited by 161
“In addition to cognitive deficits, physical features, emotional/ behavioral problems, anxiety, sleeping disturbances, and seizures [Berry-Kravis et al., 2011]; approximately 60% of individuals with FXS also have Autism Spectrum Disorders (ASDs) [Harris et al., 2008].”
Background
Metadata
- Authors
- Berry-Kravis, E., Knox, A., & Hervey, C.
- Venue
- Journal of Neurodevelopmental Disorders
- Published
- 2011-02-19
- Volume
- 3
- Issue
- 3
- Pages
- 193-210
- ISSN
- 1866-1947 (ISSN-L)
- 1866-1955
- OpenAlex
- W2026831615
- Cited by
- 103
- References
- 61
- FWCI
- 9.32
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeted treatments for fragile X syndrome. https://app.cochat.ai/papers/10.1007/s11689-011-9074-7
- The paper
- Berry-Kravis, E., Knox, A., & Hervey, C. (2011). Targeted treatments for fragile X syndrome. Journal of Neurodevelopmental Disorders. https://doi.org/10.1007/s11689-011-9074-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.